Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Journal of Clinical Medicine
|
June 19, 2019
MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection
Óscar Brochado-Kith, Alicia Gómez Sanz, Luis Miguel Real, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 10, 2025
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)
Sergio Serrano-Villar, Laura Martín-Pedraza, Juan Tiraboschi, et al.
Medicine
|
June 17, 2022
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Jesús Troya, Carlos Dueñas, Idoia Irazola, et al.
HIV Medicine
|
October 21, 2025
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort
Jesús Troya, María Luisa Montes, María José Galindo, et al.
The Journal of Antimicrobial Chemotherapy
|
September 19, 2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Daniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, et al.
AIDS (London, England)
|
March 10, 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohort
Jesús Troya, María Luisa Montes, María José Galindo, et al.
AIDS (London, England)
|
November 3, 2025
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort
Luis Buzón, José I Bernardino, María José Galindo Puerto, et al.
Trials
|
September 15, 2022
Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial
Anabel Franco-Moreno, María Soledad Acedo-Gutiérrez, Nicolás Labrador-San Martín, et al.
Ebiomedicine
|
April 19, 2021
Epigenome-wide association study of COVID-19 severity with respiratory failure
Manuel Castro de Moura, Veronica Davalos, Laura Planas-Serra, et al.
BMJ Open Respiratory Research
|
December 8, 2025
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol
Laura Diab Casares, Juan Espinosa Pereiro, María Teresa Tórtola Fernández, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Journal of Clinical Medicine
|
June 19, 2019
MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection
Óscar Brochado-Kith, Alicia Gómez Sanz, Luis Miguel Real, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 10, 2025
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)
Sergio Serrano-Villar, Laura Martín-Pedraza, Juan Tiraboschi, et al.
Medicine
|
June 17, 2022
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Jesús Troya, Carlos Dueñas, Idoia Irazola, et al.
HIV Medicine
|
October 21, 2025
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort
Jesús Troya, María Luisa Montes, María José Galindo, et al.
The Journal of Antimicrobial Chemotherapy
|
September 19, 2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Daniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, et al.
AIDS (London, England)
|
March 10, 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohort
Jesús Troya, María Luisa Montes, María José Galindo, et al.
AIDS (London, England)
|
November 3, 2025
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort
Luis Buzón, José I Bernardino, María José Galindo Puerto, et al.
Trials
|
September 15, 2022
Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial
Anabel Franco-Moreno, María Soledad Acedo-Gutiérrez, Nicolás Labrador-San Martín, et al.
Ebiomedicine
|
April 19, 2021
Epigenome-wide association study of COVID-19 severity with respiratory failure
Manuel Castro de Moura, Veronica Davalos, Laura Planas-Serra, et al.
BMJ Open Respiratory Research
|
December 8, 2025
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol
Laura Diab Casares, Juan Espinosa Pereiro, María Teresa Tórtola Fernández, et al.
Page
of 6